🔎 Trials Near Me

Beranda › Glomerulosklerosis Segmental Fokal › Texas

Uji klinis Glomerulosklerosis Segmental Fokal di Texas

5 studi untuk Glomerulosklerosis Segmental Fokal mencari peserta di lokasi di Texas.

Kota di Texas

Teks studi resmi (Bahasa Inggris)

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

  • Investigator Site #5, Arlington
  • Investigator Site #21, Dallas
  • Investigator Site #9, Dallas
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07268638

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

  • Texas Tech University Health Sciences Center-Amarillo-63885, Amarillo
  • The Healing Kidneys Institute, Conroe
  • Advanced Dallas Hospital and Clinics, Dallas
  • dan 4 lainnya
Menerima pesertaFase 3
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07220083

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

  • Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400024, Dallas
  • El Paso Kidney Specialists- Site Number : 8400005, El Paso
  • Prolato Clinical Research Center- Site Number : 8400016, Houston
Menerima pesertaFase 2
Usia 16 hingga 75 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06500702

Nephrotic Syndrome Study Network

  • University of Texas-Southwestern, Dallas
  • Texas Children's Hospital - Baylor College of Medicine, Houston
Menerima pesertaStudi observasional
Hingga usia 80 · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT01209000

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

  • Texas Children's Hospital, Houston
Menerima pesertaFase 2
Usia 1 hingga 17 · Semua jenis kelamin · Diperbarui 12 Mei 2026 · NCT05003986

Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.